GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » Short-Term Debt

RepliCel Life Sciences (RepliCel Life Sciences) Short-Term Debt : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2004. Start your Free Trial

What is RepliCel Life Sciences Short-Term Debt?

RepliCel Life Sciences's Short-Term Debt for the quarter that ended in Sep. 2023 was $0.00 Mil.

RepliCel Life Sciences's annual Short-Term Debt declined from Dec. 2020 ($0.04 Mil) to Dec. 2021 ($0.00 Mil) but then stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).


RepliCel Life Sciences Short-Term Debt Historical Data

The historical data trend for RepliCel Life Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences Short-Term Debt Chart

RepliCel Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.04 - -

RepliCel Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

RepliCel Life Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


RepliCel Life Sciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


RepliCel Life Sciences (RepliCel Life Sciences) Business Description

Traded in Other Exchanges
Address
570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.